Today, NAMI announced it has joined the Accelerating Medicines Partnership (AMP) Schizophrenia (SCZ), which brings together NIH, the U.S. Food and Drug Administration and multiple non-profit and private organizations to work toward meeting the urgent need for early therapeutic interventions for people at risk of developing schizophrenia.
Read More.